MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

today announced new clinical trial results showing the subcutaneous (SC) formulation of Orencia^® (abatacept) on a background of methotrexate (MTX) was similar to Humira^® (adalimumab) plus MTX in ...

Amgen is introducing Amjevita (adalimumab-atto), a biosimilar to AbbVie’s Humira. Amjevita was the first biosimilar to Humira approved by the Food and Drug Administration in 2016. "With today's ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...